|
| 36720863 | Single-cell analysis reveals prognostic fibroblast subpopulations linked to molecular and immunological subtypes of lung cancer. | | 2023 |
| 37676964 | Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors. | Science | 2023 |
| 37672882 | Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. | J Clin Oncol | 2023 |
| 37587913 | Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. | Cancer Res Commun | 2023 |
| 36653664 | Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. | Ann Surg Oncol | 2023 |
| 37137501 | The Breast Cancer Proteome and Precision Oncology. | Cold Spring Harb Perspect Med | 2023 |
| 37071495 | Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer. | Cancer Res | 2023 |
| 36745260 | ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy - Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2-3 Breast Cancer. | Ann Surg Oncol | 2023 |
| 36858723 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. | Lancet Oncol | 2023 |
| 37501682 | Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. | Cancer Res Commun | 2023 |
| 35348756 | Breast Cancer Treatment Delay in SafetyNet Health Systems, Houston Versus Southeast Brazil. | Oncologist | 2022 |
| 35653124 | Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031). | Clin Cancer Res | 2022 |
| 36353752 | ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance. | Cancer Research | 2022 |
| 36001024 | Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. | Cancer Discov | 2022 |
| 36273232 | Personalized ctDNA micro-panels can monitor and predict clinical outcomes for patients with triple-negative breast cancer. | Sci Rep | 2022 |
| 35736563 | Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. | Cancer Research | 2022 |
| 35418131 | LINC00355 regulates p27<sup>KIP</sup> expression by binding to MENIN to induce proliferation in late-stage relapse breast cancer. | NPJ Breast Cancer | 2022 |
| 35860837 | Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. | Therapeutic Advances in Medical Oncology | 2022 |
| 36619972 | Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. | iScience | 2022 |
| 35046057 | The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. | Clin Cancer Res | 2022 |
| 35236940 | Cancer proteogenomics: current impact and future prospects. | Nat Rev Cancer | 2022 |
| 34996889 | Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. | Nat Commun | 2022 |
| 34429404 | Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. | Nat Commun | 2021 |
| 33543355 | Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer. | Breast Cancer Research and Treatment | 2021 |
| 33542078 | Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. | Clinical Cancer Research | 2021 |
| 34173924 | Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer. | Breast Cancer Res Treat | 2021 |
| 34011995 | Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. | Nature Communications | 2021 |
| 34218359 | A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. | Breast Cancer Res Treat | 2021 |
| 34048027 | Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer. | Clin Pharmacol Ther | 2021 |
| 33997789 | CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. | Nat Cancer | 2021 |
| 33878299 | The bone microenvironment increases phenotypic plasticity of ER<sup>+</sup> breast cancer cells. | Dev Cell | 2021 |
| 33450205 | Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. | Cell | 2021 |
| 33257837 | RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. | Br J Cancer | 2021 |
| 33369635 | Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. | J Natl Cancer Inst | 2021 |
| 32986828 | Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. | J Natl Cancer Inst | 2021 |
| 32649577 | Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer. | Pharmacogenet Genomics | 2021 |
| 33417831 | Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. | Cancer Cell | 2021 |
| 34711608 | Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. | Cancer Res | 2021 |
| 31522348 | Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. | Breast Cancer Res Treat | 2020 |
| 32142667 | Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer. | Cancer Cell | 2020 |
| 32191303 | Response to Jézéquel, Patsouris, Guette, et al. | Journal of the National Cancer Institute | 2020 |
| 31690650 | CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree? | Clinical Cancer Research | 2020 |
| 32309212 | Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy. | Frontiers in Oncology | 2020 |
| 31566680 | Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. | JAMA Oncol | 2020 |
| 32098767 | Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α. | Clin Cancer Res | 2020 |
| 31665365 | Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). | J Natl Cancer Inst | 2020 |
| 33371187 | Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models. | Cancers (Basel) | 2020 |
| 32701512 | Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action. | JCI Insight | 2020 |
| 32564259 | Correction to: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. | Breast Cancer Res Treat | 2020 |
| 32720716 | Glutamine deprivation alters the origin and function of cancer cell exosomes. | EMBO J | 2020 |